ImmuCell Corp (FRA:IUL)

Q4 2024 ImmuCell Corp Earnings Call Transcript

Feb 26, 2025 / 02:00 PM GMT

Release Date Price: €4.78 (-0.42%)

Transcript 8-K

Key Points

Positve

ImmuCell Corp (ICCC) reported a significant sales growth of 52% during both the fourth quarter and the full year of 2024 compared to the previous year.
The company achieved a gross margin increase of 125% in the fourth quarter of 2024, reaching $2.8 million, indicating improved financial performance.
ImmuCell Corp (ICCC) successfully remediated previous production contamination issues, with no new events since April 2024, suggesting improved operational stability.
The company raised net proceeds of almost $4.4 million during 2024, enhancing its cash position to approximately $3.8 million by the end of the year.
ImmuCell Corp (ICCC) is poised to revolutionize the treatment of subclinical mastitis with its novel product, Retain, which is pending FDA approval and could offer a significant market opportunity.

Negative

The company's gross margin percentage, although improved, is still below the target of over 40%, indicating room for further operational efficiency.
Production contamination events in 2023 and early 2024 led to reduced manufacturing output and delayed capacity expansion, impacting sales and operations.
The company faces challenges in maintaining consistent production yields due to biological processing variances, which could affect future output and margins.
ImmuCell Corp (ICCC) has a significant investment of about $50 million and 25 years in developing Retain, with ongoing regulatory hurdles delaying its market launch.
The company experienced a substantial increase in inventory levels due to contracted milk deliveries and unforeseen production slowdowns, impacting cash flow management.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ICCC.OQ - ImmuCell Corp
Q4 2024 ImmuCell Corp Earnings Call
Feb 26, 2025 / 02:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning and welcome to Inusel Corporation reports its 4th quarter and year ended December 31, 2024 unauuddied financial results conference call. All participants will be in listen-only mode. After today's presentation, there will be an opportunity to ask questions. Please note this event is being recorded.

I would now like to turn the conference over to Joe Diaz of Litham Partners. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you Debbie. Good morning and welcome to all. As conference call operator indicated, my name is Joe Diaz. I'm with Liam Partners. We

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.